Skip to main content
. 2024 Mar 14;16(3):397. doi: 10.3390/pharmaceutics16030397

Figure 15.

Figure 15

(a) TP5 cumulative amount with or without niosomes in the absence or presence of variable inhibitors and penetration enhancers for 6 h transport study at 37 °C (Mean ± S.D., n = 6); (b) TP5 cumulative amount with or without PEG-niosomes in the absence or presence of variable inhibitors and penetration enhancers for 6 h transport study at 37 °C (Mean ± S.D., n = 6).